Mini antibodies: biotech's next big thing?
LONDON (Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.
<p><img src="http://feeds.reuters.com/~a/reuters/scienceNews?i=KOSRn5" border="0"></img> (http://feeds.reuters.com/~a/reuters/scienceNews?a=KOSRn5)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=SuVeL" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=SuVeL) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=Lz9ql" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=Lz9ql) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=Yqcul" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=Yqcul)
</div><img src="http://feeds.reuters.com/~r/reuters/scienceNews/~4/390477516" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/scienceNews/~3/390477516/idUSLC56746320080912